97269 ⎘
Immunoglobulins specific features characterized by post-translational modification
Sub-classes:ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
#2Cysteine Engineered Antibodies and Conjugates
#3ANTI-CTLA4 ANTIBODIES AND METHODS OF USE THEREOF
#4Antibodies Binding to ILT4
#5ANTI-B7H3 ANTIBODIES AND METHODS OF USE
#6SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES
#7Methods for Standardizing Lectin Reagents, IgA1 Calibration Standards, and Quantitative Measurement of Galactose-Deficient IgA1 in Human Samples
#8THIAZOLIDINE LINKERS FOR PROTEIN-DRUG CONJUGATES AND USES THEREOF
#9ANTI-SIGLEC-15 ANTIBODY AND USE THEREOF
#10BISPECIFIC HER2 AND CD3 BINDING MOLECULES
#11MUTANT PROMOTING HOMOLOGOUS PAIRING OF HEAVY AND LIGHT CHAINS OF MULTISPECIFIC ANTIBODY
#12METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE, ALLERGIC AND INFLAMMATORY DISEASES
#13BIOPHARMACEUTICAL COMPOSITIONS
#14ANTI-CORTICOTROPIN-RELEASING HORMONE ANTIBODIES AND POLYCYSTIC OVARY SYNDROME
#15PROCESS FOR MANUFACTURING ANTIBODY FRAGMENT PROTEIN
#16METHOD OF CONJUGATION OF CYS-MABS
#17ANTI-CD16A ANTIBODIES AND METHODS OF USE THEREOF
#18FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME
#19ENZYME AND PATHWAY MODULATION WITH SULFHYDRYL COMPOUNDS AND THEIR DERIVATIVES
#20Anti-CTLA Antibody Compositions and Related Methods
#21CANINE ANTIBODY LIBRARIES
#22COMPOSITIONS AND METHODS RELATED TO IL2 RECEPTOR BINDING
#23TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF Fab
#24Anti-B7H3 antibody and Uses thereof
#25ANTI-B7-H3 ANTIBODIES AND USES THEREOF
#26ACTIVATABLE MASKED ANTI-CTLA4 BINDING PROTEINS
#27PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES
#28ANTI-C-C MOTIF CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES AND METHODS OF USE
#29ANTIBODIES TARGETING IL-18 RECEPTOR BETA (IL-18RB) AND RELATED METHODS
#30CHARGED DEPTH FILTRATION OF ANTIGEN-BINDING PROTEINS
#31POLYNUCLEOTIDES ENCODING ANTIBODIES WHICH BIND THE EC3 DOMAIN OF CADHERIN-6 (CDH6) AND POSSESS INTERNALIZATION ABILITY
#32METHODS OF USE OF ANTI-SORTILIN ANTIBODIES
#33ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF
#34ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF
#35ANTI-CORTICOTROPIN-RELEASING HORMONE ANTIBODIES AND USE IN CONGENITAL ADRENAL HYPERPLASIA
#36ANTIBODY COMPOSITIONS FOR DISRUPTING BIOFILMS
#37ANTI-5T4 ANTIBODIES AND USES THEREOF
#38ANTIBODY TARGETING CD25, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#39ANTIBODY, IMMOBILIZED ANTIBODY USING THE SAME, ANTIBODY COMPOSITION, REAGENT FOR IMMUNOASSAY AND IMMUNOASSAY METHOD, AS WELL AS METHOD FOR IMPROVING REACTIVITY OF ANTIBODY WITH ANTIGEN
#40MODIFIED PROTEINS AND PEPTIDES
#41MUC1 and CD16A Antibodies and Methods of Use
#42SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING
#43LIPOSOME ENCAPSULATED AFFINITY DRUG
#44SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES
#45ANTIBODIES AND METHODS OF USE
#46CIRCULARIZED ANTIBODY MOLECULES
#47ICOS LIGAND VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#48COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS
#49ANTI-FOLATE RECEPTOR ANTIBODIES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODIES AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODIES
#50ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF
#51ANTIBODIES FOR THE TREATMENT OF AML
#52HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF
#53ANTI-CD25 ANTIBODY AGENTS
#54ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
#55ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
#56Biopharmaceutical compositions
#57Biopharmaceutical compositions
#58Biopharmaceutical compositions
#59INTERLEUKIN-15 BASED IMMUNOCYTOKINES
#60TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF Fab
#61MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF
#62HYPERGLYCOSYLATED BINDING POLYPEPTIDES
#63ANTI-PD-1 SIGNAL PEPTIDE ANTIBODY AND USE THEREOF
#64Anti-TSPAN8/anti-CD3 bispecific antibody and anti-TSPAN8 antibody
#65GLYCOFORM SPECIFIC NANOBODIES AND METHODS OF USE
#66ANTI-TN ANTIBODIES AND USES THEREOF
#67ANTI-SARS CORONAVIRUS-2 NUCLEOCAPSID PROTEIN ANTIBODIES
#68ANTIBODIES AND METHODS OF USE
#69CANINE ANTIBODY LIBRARIES
#70ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
#71Activated formylglycine-generating enzymes and methods of producing and using the same
#72Anti-TSPAN8/anti-CD3 bispecific antibody and anti-TSPAN8 antibody
#73ENZYME AND PATHWAY MODULATION WITH SULFHYDRYL COMPOUNDS AND THEIR DERIVATIVES
#74CELL PENETRATING PROTEIN-ANTIBODY CONJUGATES AND METHODS OF USE
#75METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
#76Polynucleotides encoding antibodies which bind the EC3 domain of cadherin-6 (CDH6) and possess internalization ability
#77RECOMBINANT ANTIBODY HAVING UNIQUE GLYCAN PROFILE PRODUCED BY CHO HOST CELL WITH EDITED GENOME AND PREPARATION METHOD THEREOF
#78Antibodies Binding to ILT4
#79PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES
#80AFFINITY MATURED AND HUMANIZED BINDING DOMAINS TARGETING ROR2
#81BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF
#82Anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of use
#83COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS
#84MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF
#85PROTEINS COMPRISING CD3 ANTIGEN BINDING DOMAINS AND USES THEREOF
#86BIOPHARMACEUTICAL COMPOSITIONS
#87MONOCLONAL ANTIBODY OR ANTIBODY FRAGMENT AGAINST CANINE CD20
#88GLYCOSYLATED IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#89Copper supplementation for control of glycosylation in mammalian cell culture process
#90SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES
#91Methods of Purifying Masked Antibodies
#92Anti-PACAP antibodies and uses thereof
#93MODIFIED HUMAN VARIABLE DOMAINS
#94GLUCURONYLATION AS A NEW ACIDIC POST-TRANSLATIONAL MODIFICATION ON THERAPEUTIC MONOCLONAL ANTIBODIES
#95Antibody library and antibody screening method using same
#96Antibody compositions for disrupting biofilms
#97Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
#98CD33 ANTIBODIES AND METHODS OF USING THE SAME TO TREAT CANCER
#99ANTI-CSF-IR ANTIBODY
#100Biopharmaceutical compositions
#101MULTISPECIFIC BINDING PROTEINS
#102TAG FOR LABELING BIOMOLECULES
#103Anti-CD94 antibodies and methods of use thereof
#104Antibodies to MAdCAM
#105KAWASAKI DISEASE ANTIBODIES IDENTIFY HEPACIVIRUS PEPTIDES
#106PREVENTION OF PROTEIN DISULFIDE BOND REDUCTION
#107Site-specific antibody-drug conjugation through glycoengineering
#108Manufacturing Methods To Control C-Terminal Lysine, Galactose And Sialic Acid Content In Recombinant Proteins
#109GLYCOENGINEERED ANTIBODY DRUG CONJUGATES
#110C-terminal lysine conjugated immunoglobulins
#111BISPECIFIC ANTIBODY EXHIBITING INCREASED ALTERNATIVE FVIII-COFACTOR-FUNCTION ACTIVITY
#112ACTIVATABLE MASKED ANTI-CTLA4 BINDING PROTEINS
#113ANTIBODIES AND METHODS OF USE
#114ANTI-CTLA4 ANTIBODIES AND METHODS OF USE THEREOF
#115USE OF TIM-3 ANTIBODY IN PREPARATION OF MEDICINES FOR TREATING TUMORS
#116Activated formylglycine-generating enzymes and methods of producing and using the same
#117CHARGED DEPTH FILTRATION OF ANTIGEN- BINDING PROTEINS
#118DECOY POLYPEPTIDES
#119METHOD OF CONJUGATION OF CYS-MABS
#120Biopharmaceutical compositions
#121Biopharmaceutical compositions
#122Biopharmaceutical compositions
#123Screening method for identifying anti-PACAP antibodies or antibody fragments suitable for use in treating or preventing PACAP-associated photophobia or light aversion
#124Canine antibody libraries
#125Mesothelin and CD137 binding molecules
#126Methods and compositions for treating autoimmune and inflammatory conditions
#127Methods of treatment with anti-PACAP antibodies
#128BISPECIFIC ANTIBODIES
#129ANTI-CD137 ANTIBODIES
#130METHODS OF GLYCOPROTEIN ANALYSIS
#131Antibody compositions for disrupting biofilms
#132ICOS ligand variant immunomodulatory proteins and uses thereof
#133Sodium channel inhibitors
#134Lysine conjugated immunoglobulins
#135Optimized Fc variants
#136Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
#137Anti-transglutaminase 2 antibodies
#138CONJUGATED COMPOUNDS COMPRISING CYSTEINE-ENGINEERED ANTIBODIES
#139IgG4 Fc fragment comprising modified hinge region
#140Anti-CD25 antibody agents
#141Anti-CD25 for tumour specific cell depletion
#142Anti-CD25 for tumour specific cell depletion
#143METHOD FOR TREATING SEIZURES
#144Compositions and methods for antibodies targeting BMP6
#145Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification
#146MODIFIED PROTEINS AND PEPTIDES
#147Anti-CD25 for tumour specific cell depletion
#148Anti-CD25 for tumour specific cell depletion
#149Anti-CD25 for tumour specific cell depletion
#150Anti-CD25 antibody agents
#151Anti-CD25 antibody agents
#152FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME
#153PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
#154Anti-annexin A2 monoclonal antibodies
#155METHODS OF USE OF ANTI-SORTILIN ANTIBODIES
#156METHOD FOR THE PRODUCTION OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#157Anti-CDH6 antibody and anti-CDH6 antibody-drug conjugate
#158Activated formylglycine-generating enzymes and methods of producing and using the same
#159Anti-tryptase antibodies, compositions thereof, and uses thereof
#160Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
#161PHARMACEUTICAL COMPOSITION COMPRISING PEGYLATED FAB' FRAGMENT OF ANTI-HUMAN NGF ANTIBODY
#162ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
#163TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF Fab
#164Immunoconjugates with an intracellularly-cleavable linkage
#165Afucosylated monoclonal antibody
#166Anti-human MUC1 antibody Fab fragment
#167B7-H4 antibodies and methods of use thereof
#168ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
#169Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
#170Canine antibody libraries
#171Recombinant antibody having unique glycan profile produced by CHO host cell with edited genome and preparation method thereof
#172Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
#173X-display complexes for protein screening methods
#174Anti-PACAP antibodies
#175NOVEL ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT
#176Anti-CDH6 antibody and method of producing an anti-CDH6 antibody-drug conjugate
#177Covalently linked antigen-antibody conjugates
#178Antibodies of the class IGG4
#179SUBTYPES OF HUMANIZED ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR
#180Anti-CLL-1 antibodies and methods of use
#181Hyperglycosylated binding polypeptides
#182T-cell modulatory multimeric polypeptides and methods of use thereof
#183Engineered antibodies for the detection of phosphorylated tyrosine
#184Purification process for removal of tyrosine sulfation antibody variants; purified compositions
#185Immunoconjugates with an intracellularly-cleavable linkage
#186T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
#187Analysis of Disulfide Bonds
#188ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
#189Antibodies binding to ILT4
#190Anti-PACAP antibodies
#191METHOD FOR THE PRODUCTION OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#192COMPOSITION COMPRISING AVELUMAB
#193Homogenous antibody drug conjugates via enzymatic methods
#194MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE
#195C-terminal lysine conjugated immunoglobulins
#196Activated formylglycine-generating enzymes and methods of producing and using the same
#197METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
#198Antibodies recognizing genetic variants of NT-proBNP
#199Anti-tryptase antibodies, compositions thereof, and uses thereof
#200Bispecific HER2 and CD3 binding molecules
#201Anti-ICOS antibodies
#202ANTI-LAG3 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-LAG3 ANTIBODIES AND METHODS OF MAKING AND USING ANTI-LAG3 ANTIBODIES
#203DEGLYCOSYLATED ANTIBODY SPECIFICALLY BINDING TO CLEC14A AND USES THEREOF
#204Anti-human MUC1 antibody Fab fragment
#205Anti-canine platelet derived growth factor receptor alpha antibody
#206Methods of determining whether anti-PACAP antibodies inhibit PACAP-associated photophobia or light aversion
#207Mixtures of antibodies
#208Glucuronylation as a new acidic post-translational modification on therapeutic monoclonal antibodies
#209Site-specific antibody-drug conjugation through glycoengineering
#210ANTI-FOLATE RECEPTOR ANTIBODIES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODIES AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODIES
#211Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
#212BISPECIFIC ANTIBODY EXHIBITING INCREASED ALTERNATIVE FVIII-COFACTOR-FUNCTION ACTIVITY
#213Host cell comprising nucleic acids encoding bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1 and antibody production
#214Anti-annexin A2 monoclonal antibodies
#215Immunoconjugates with an intracellularly-cleavable linkage
#216Compositions and methods for inducing apoptosis
#217Aldehyde tags, uses thereof in site-specific protein modification
#218Modified Fc molecules
#219Monomeric proteins and uses thereof
#220METHOD AND MEANS FOR DETECTING THE LEVEL OF TOTAL VEGF-A
#221Methods of treatment using activatable anti-EGFR antibodies
#222B7-H4 antibodies and methods of use thereof
#223Fc variants with increased affinity for FcγRIIc
#224Glycoengineered antibody drug conjugates
#225HUMAN ANTIBODIES THAT BIND HUMAN TNF-ALPHA AND METHODS OF PREPARING THE SAME
#226Antibodies for the treatment of cancers
#227Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
#228Process for preparing purified drug conjugates
#229Anti-HER2 glycoantibodies and uses thereof
#230PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF
#231Homogenous antibody drug conjugates via enzymatic methods
#232Homogenous antibody drug conjugates via enzymatic methods
#233Anti-transglutaminase 2 antibodies
#234PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
#235Nucleic acids encoding anti-Factor P antibodies
#236Pyrrolobenzodiazepine antibody drug conjugates and methods of use
#237Immunoconjugates with an intracellularly-cleavable linkage
#238T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
#239Methods of preventing and removing trisulfide bonds
#240Antibody Fragments Against the Insulin Receptor and Uses Thereof to Treat Hypoglycemia
#241Fusion immunomodulatory proteins and methods for making same
#242Biopharmaceutical compositions comprising interleukin-5 antibody
#243RADIOLABELED ANTI-GLYPICAN-3 IMMUNOCONJUGATES FROM IMMUNO-PET IMAGING OF HEPATOCELLULAR CARCINOMA
#244Cell penetrating protein-antibody conjugates and methods of use
#245Anti-tryptase antibodies, compositions thereof, and uses thereof
#246SUBTYPES OF HUMANIZED ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR
#247Charged depth filtration of antigen-binding proteins
#248Activated formylglycine-generating enzymes and methods of producing and using the same
#249Meditopes and meditope-binding antibodies and uses thereof
#250Eribulin-based antibody-drug conjugates and methods of use
#251Enzymatic conjugation of antibodies
#252Pyrrolobenzodiazepine antibody drug conjugates and methods of use
#253Compositions and methods for antibodies targeting BMP6
#254Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
#255Conjugated compounds comprising cysteine-engineered antibodies
#256DE-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
#257Methods of glycoprotein analysis
#258Anti-human NGF antibody Fab fragment and methods for treating postoperative pain related to NGF
#259ENGINEERED SITE-SPECIFIC ANTIBODIES AND METHODS OF USE
#260SINGLE CHAIN PROTEINS WITH C-TERMINAL MODIFICATIONS
#261Nucleic acids encoding bispecific antibodies binding to beta-Klotho and fibroblast growth factor receptor 1
#262Protein screening methods
#263Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
#264ENZYMATIC CONJUGATION OF POLYPEPTIDES
#265Lysine conjugated immunoglobulins
#266Glycosylated immunoglobulin single variable domains
#267NOVEL ANTI-FIBROBLAST ACTIVATION PROTEIN (FAP) BINDING AGENTS AND USES THEREOF
#268Modulation of charge variants in a monoclonal antibody composition
#269Hyperglycosylated binding polypeptides
#270Selective reduction of cysteine residues in IL-17 antibodies
#271METHODS TO MODULATE LYSINE VARIANT DISTRIBUTION
#272Copper supplementation for control of glycosylation in mammalian cell culture process
#273ICOS ligand variant immunomodulatory proteins and uses thereof
#274Stabilized and autonomous antibody VH domain
#275Enzymatic one-pot reaction for double polypeptide conjugation in a single step
#276Cell lines
#277Amino acid derivatives
#278Site-specific antibody-drug conjugation through glycoengineering
#279Immunoconjugates with an intracellularly-cleavable linkage
#280Anti-human tie-2 antibody
#281Eribulin-based antibody-drug conjugates and methods of use
#282Methods of preventing and removing trisulfide bonds
#283Immunoconjugates with an intracellularly-cleavable linkage
#284Method for screening for autophagy activator or inhibitor
#285IN VIVO SITE-SPECIFIC PROTEIN TAGGING USING ENGINEERED SORTASE VARIANTS
#286Conjugates of an anti-TNF-alpha antibody
#287Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
#288Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
#289BIOLOGICAL PRODUCTS
#290Fab FRAGMENT SPECIFICALLY BINDING TO EGFR
#291Deglycosylation reagents and methods
#292Aldehyde tags, uses thereof in site-specific protein modification
#293ANTIBODY HAVING INFECTION-INHIBITING ACTIVITY AGAINST HEPATITIS C VIRUS
#294Homogenous antibody drug conjugates via enzymatic methods
#295Methods and compositions for treating autoimmune and inflammatory conditions
#296Pyrrolobenzodiazepine antibody drug conjugates and methods of use
#297Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
#298Compositions and methods related to anti-EGFR antibody drug conjugates
#299Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV
#300Molecular imprinting of West Nile antibodies with physiological pH matching